HemoCue Runs Higher Than Cyanmethemoglobin in Young Children, Distorting Anemia Estimates
In children aged 6 to 24 months, hemoglobin measurement is not a technical footnote. It is the hinge on which anemia prevalence estimates, nutrition programs, and treatment thresholds turn. In a Bangladeshi validation study, the widely used HemoCue 201 instrument consistently read higher than the direct cyanmethemoglobin method, creating exactly the kind of upward bias that can make anemia appear less common than it truly is.
The analysis drew on venous blood samples collected in Mirpur, Dhaka, from February 2010 through February 2017 as part of the Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development study. Investigators compared HemoCue 201 against the direct cyanmethemoglobin, or DCM, method in 846 venous samples from 589 children under two years of age. The sample size gives the work weight, and the repeated sampling from the same cohort adds a practical dimension: this was not a one-off comparison in a tightly controlled laboratory subset, but a field-relevant assessment of a device used every day in resource-limited settings.
The median hemoglobin concentration measured by HemoCue was 11.6 g/dL, with an interquartile range of 10.5 to 12.5 g/dL. The DCM method produced a lower median of 10.8 g/dL, with an interquartile range of 10.1 to 11.5 g/dL. The gap is clinically meaningful. In pediatric screening, a difference of less than 1 g/dL can move a child across the anemia threshold, alter prevalence estimates for a community, and change how health systems allocate iron supplementation, counseling, and follow-up.
One sentence captures the core problem: HemoCue read systematically higher than the reference method.
Why the Bias Matters in Infant Anemia Screening
The biological and operational reasons matter here. Capillary- or venous-based point-of-care devices are prized because they are fast, portable, and feasible where laboratory infrastructure is thin. Yet small analytic shifts in hemoglobin concentration can have outsized consequences when the clinical endpoint is binary, as it is in anemia classification. If the device overestimates hemoglobin, fewer children will be labeled anemic. Prevalence estimates fall on paper while the underlying burden in the population remains unchanged.
This is especially consequential in infants and toddlers, whose iron stores, growth velocity, dietary transitions, and susceptibility to enteric illness make them vulnerable to anemia. Underestimation delays recognition of a preventable problem during a developmental window when deficiency can affect neurocognitive and physical growth. In public health terms, a biased screening tool does not just misclassify individuals; it can distort surveillance, obscure program impact, and weaken resource planning.
Attempted Calibration Did Not Produce a Stable Correction Model
The investigators explored quadratic regression to derive a correction factor for HemoCue readings, but the spread of measurements was too wide to support a dependable model. In plain clinical terms, the scatter around the HemoCue values was too great for a single mathematical adjustment to work well across the observed range. That is a significant finding on its own. It means the problem is not just a fixed offset that can be subtracted from every result; the discrepancy is more erratic than that.
That matters because many point-of-care validations assume a relatively predictable relationship between the index test and the reference method. If the deviation varies across measurements, a universal correction factor can mislead clinicians and field teams just as easily as the original device reading. The study therefore points away from simple recalibration and toward a more cautious approach to interpretation when HemoCue is used in young children.
A Revised Threshold Was Sought to Improve Diagnostic Balance
Youden’s Index was used to identify an optimal hemoglobin cut-off, but the investigators also aimed for at least 70% sensitivity and specificity to preserve diagnostic balance. That dual goal reflects a familiar tension in screening: a threshold that is too high can miss true anemia, while one that is too low can overcall disease and burden families and services with unnecessary follow-up. The text provided here does not include the final cut-off value, so it cannot be reconstructed without risking invention.
Even without the missing threshold, the direction of travel is clear. When a field device consistently reports hemoglobin above a reference laboratory method, the anemia cut-off used in practice may need revision if prevalence estimates are to remain credible. In children under two, this is not a minor statistical adjustment; it is a recalibration of how a common pediatric problem is counted.
What Clinicians and Program Planners Should Take From the Data
This validation study reinforces a familiar but often underappreciated principle in global child health: a screening instrument is only as useful as its agreement with the method it is meant to approximate. HemoCue remains attractive because it is portable and fast, but these data show that portability does not guarantee equivalence. When the device reads higher than DCM, anemia burden will be underestimated unless the threshold is adjusted or the measurement strategy is reconsidered.
For clinicians working in settings where HemoCue is the default tool, the implications are immediate. A child whose hemoglobin appears borderline normal on HemoCue may merit more cautious interpretation if the program relies on this platform for anemia surveillance. For public health teams, prevalence maps derived from uncorrected point-of-care readings may systematically understate the need for iron-focused intervention. For researchers, any future field study using HemoCue in this age group will need to account for method bias before concluding that anemia rates have truly improved.
The study also leaves an important practical question unresolved in the material available here: what exact revised cut-off best balanced sensitivity and specificity in this cohort? Without the final threshold, implementation remains incomplete. The broader message, however, is already established by the data that are available: in Bangladeshi children aged 6 to 24 months, HemoCue overestimated hemoglobin relative to DCM, and simple correction modeling did not provide a robust fix.